- Home
- PHAR vs HKD Comparison
PHAR vs HKD Comparison
Compare PHAR & HKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHAR | HKD |
|---|---|---|
| Founded | 1988 | 2003 |
| Country | Netherlands | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 487.1M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | PHAR | HKD |
|---|---|---|
| Price | $16.31 | $1.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $38.00 | N/A |
| AVG Volume (30 Days) | 22.5K | ★ 452.9K |
| Earning Date | 11-06-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $362,274,000.00 | $87,436,000.00 |
| Revenue This Year | $24.80 | N/A |
| Revenue Next Year | $6.84 | N/A |
| P/E Ratio | $2,946.57 | ★ $11.76 |
| Revenue Growth | ★ 26.78 | N/A |
| 52 Week Low | $7.50 | $1.33 |
| 52 Week High | $18.12 | $5.47 |
Technical Indicators
Market Signals| Indicator | PHAR | HKD |
|---|---|---|
| Relative Strength Index (RSI) | 51.06 | 39.59 |
| Support Level | $16.23 | $1.33 |
| Resistance Level | $17.00 | $1.43 |
| Average True Range (ATR) | 0.75 | 0.08 |
| MACD | -0.16 | -0.01 |
| Stochastic Oscillator | 36.44 | 12.89 |
Price Performance
Historical ComparisonAbout PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About HKD AMTD Digital Inc. (every five of which represent two)
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment, hotel operations, hospitality and VIP services segment and media and entertainment services. The company generates maximum revenue by providing financial digital solutions through its insurance brokerage services and other digital solutions services. Geographically, the company generates maximum revenue from Hong Kong and Singapore.